You are here: Industry Insights > Huntington’s Disease

News List

Ipsen and Exicure to develop therapies for neurodegenerative disorders pharmaceutical-technology
August 04, 2021
Ipsen and Exicure have entered an exclusive partnership agreement for the research, development and marketing of new spherical nucleic acids (SNAs) for the potential treatment of Huntington’s disease and Angelman syndrome.
Roche ends tominersen study in manifest Huntington’s disease pharmatimes
March 24, 2021
Swiss pharma company Roche has announced that it will discontinue dosing in a Phase III study evaluating its investigational candidate tominersen in manifest Huntington’s disease.
Novartis’ branaplam gets orphan drug designation for Huntington’s disease pharmaceutical-technology
October 22, 2020
The US Food and Drug Administration (FDA) has granted orphan drug designation to Novartis’ branaplam (LMI070) to treat Huntington’s disease.
Top-Line Results Released from Huntington’s Disease Study americanpharmaceuticalreview
September 27, 2020
Vaccinex announced topline results from the early manifest treatment arm (Cohort B1, N=179) of the Phase 2 double-blind, placebo-controlled SIGNAL trial of its lead clinical candidate, pepinemab, in patients with early manifest and ...
Teva Pharm gets approval in China for Huntington’s treatment expresspharma
May 19, 2020
Austedo, the drug, was included in China’s fast-tracked approval channel as a rare disease treatment of “significant clinical advantage”.
Triplet Therapeutics launches to focus on Huntington’s disease drugs pharmaceutical-technology
December 19, 2019
Biotechnology company Triplet Therapeutics has launched to develop treatments for more than 40 triplet repeat disorders, including Huntington’s disease.
Huntington’s Disease (HD) – opportunity analysis and forecast to 2024 pharmaasia
January 13, 2017
Increasing CAGR across the seven major markets, and a late-stage pipeline is set to change the landscape of HD treatment.